CIK 0001580149 · Non-accelerated filer<br>Smaller reporting company
BIOVIE INC.
Sign in to watch- Ticker
- BIVI
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Jun 30
- Incorporated
- NV
- Entity type
- operating
- EIN
- 462510769
- Phone
- 775-888-3162
- Business address
- 680 W NYE LANE, SUITE 201, CARSON CITY, NV, 89703
- Former names
- NANOANTIBIOTICS, INC.
Securities
- BIVI Common stock Nasdaq
- BIVIW Warrant Nasdaq
- Open-market buys, last 90 days
- $49,118
- in 4 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Net +$49,118. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-06-07 | Palumbo Joseph M Chief Medical Officer | Grant or award · Stock Option (right to buy) | +30,000 | 30,000 | ||
| 2023-06-07 | BERMAN RICHARD J Director | Sale | −5,984 | $5.81 | $35K | 23,210 |
| 2023-05-22 | BERMAN RICHARD J Director | Sale | −5,000 | $6.50 | $33K | 29,194 |
| 2023-03-28 | BERMAN RICHARD J Director | Sale | −5,000 | $8.52 | $43K | 36,807 |
| 2023-03-28 | BERMAN RICHARD J Director | Sale | −2,613 | $8.52 | $22K | 34,194 |
| 2023-03-27 | BERMAN RICHARD J Director | Sale | −3,371 | $8.52 | $29K | 41,807 |
| 2023-02-16 | Palumbo Joseph M Chief Medical Officer | Shares withheld for taxes | −2,476 | $5.51 | $14K | 34,672 |
| 2023-02-16 | KIM JOANNE WENDY Chief Financial Officer | Shares withheld for taxes | −2,476 | $5.51 | $14K | 41,672 |
| 2023-02-16 | DO CUONG V President & CEO | Shares withheld for taxes | −4,953 | $5.51 | $27K | 430,901 |
| 2023-02-16 | Palumbo Joseph M Chief Medical Officer | Shares withheld for taxes | −2,476 | $6.12 | $15K | 37,148 |
| 2023-02-16 | KIM JOANNE WENDY Chief Financial Officer | Shares withheld for taxes | −2,476 | $6.12 | $15K | 39,148 |
| 2023-02-16 | DO CUONG V CEO & President | Shares withheld for taxes | −4,953 | $6.12 | $30K | 229,895 |
| 2023-02-16 | Ahlem Clarence N. EVP Neuroscience Product Dev. | Shares withheld for taxes | −2,476 | $6.12 | $15K | 37,148 |
| 2023-02-16 | READING CHRISTOPHER EVP Neuroscience R&D | Shares withheld for taxes | −2,476 | $6.12 | $15K | 37,148 |
| 2023-02-16 | MARKHAM PENELOPE EVP Liver Cirrhosis R&D | Shares withheld for taxes | −2,476 | $6.12 | $15K | 47,841 |
| 2022-11-23 | ROGICH SIGMUND Director | Grant or award · STOCK OPTION (RIGHT TO BUY) | +55,000 | 55,000 | ||
| 2022-11-23 | GORLIN STEVE Director | Grant or award | +34,240 | 84,240 | ||
| 2022-11-23 | Sherman Michael Edward Director | Grant or award · STOCK OPTION (RIGHT TO BUY) | +75,000 | 75,000 | ||
| 2022-11-23 | Lang James Paul Director | Grant or award | +43,578 | 68,622 | ||
| 2022-11-23 | READING CHRISTOPHER EVP Neuroscience R&D | Grant or award | +39,624 | 39,624 |
Page 4 of 10 · 193 trades